Initial hypertension treatment: one combination fits most?
Tài liệu tham khảo
Chobanian, 2003, The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. The JNC 7 Report, JAMA, 289, 2560, 10.1001/jama.289.19.2560
Law, 2009, Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomized trials in the context of expectation from prospective epidemiological studies, BMJ, 338, b1665, 10.1136/bmj.b1665
Eagan, 2010, US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008, JAMA, 303, 2043, 10.1001/jama.2010.650
Chobanan, 2009, The hypertension paradox—more uncontrolled disease despite improved therapy, N Engl J Med, 361, 878, 10.1056/NEJMsa0903829
Mancia, 2009, Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document, J Hypertension, 27, 2121, 10.1097/HJH.0b013e328333146d
Feldman, 2009, A simplified approach to the treatment of uncomplicated hypertension. A cluster randomized, controlled trial, Hypertension, 53, 646, 10.1161/HYPERTENSIONAHA.108.123455
Egan, 2009, Fixed-dose combinations and hypertension control in community-based practices. Application of the “keep-it-simple” principal, Hypertension, 53, 589, 10.1161/HYPERTENSIONAHA.109.128678
Staessen, 2010, Implications of recently published trials of blood pressure-lowering drugs in hypertension or high-risk patients, Hypertension, 55, 819, 10.1161/HYPERTENSIONAHA.108.122879
2000, Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients, N Engl J Med, 342, 145, 10.1056/NEJM200001203420301
Jamerson, 2004, Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension, Am J Hypertens, 17, 495, 10.1016/j.amjhyper.2004.02.003
Franklin, 2009, Initial combination therapy for rapid and effective control of moderate and severe hypertension, J Human Hypertens, 23, 4, 10.1038/jhh.2008.72
Bangalore, 2007, Fixed-dose combinations improve medication compliance: a meta-analysis, Am J Med, 120, 713, 10.1016/j.amjmed.2006.08.033
Gupta, 2010, Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents. A meta-analysis, Hypertension, 55, 399, 10.1161/HYPERTENSIONAHA.109.139816
Dahlof, 2009, Management of cardiovascular risk with RAS inhibitor/CCB combination therapy, J Hum Hypertens, 23, 77, 10.1038/jhh.2008.88
Corrao, 2010, Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice, J Hypertens, 28, 1584, 10.1097/HJH.0b013e328339f9fa
Gradman, 2010, ASH Position Article. Combination therapy in hypertension, J Am Soc Hypertens, 4, 42, 10.1016/j.jash.2010.02.005
Wald, 2009, Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials, Am J Med, 122, 290, 10.1016/j.amjmed.2008.09.038
Flack, 2009, Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study, J Human Hypertens, 23, 479, 10.1038/jhh.2008.153
Carter, 2009, Fixed-dose combinations are not indicated as initial therapy: a debate, J Clin Hypertens, 11, 94, 10.1111/j.1751-7176.2009.00078.x
Berlowitz, 2010, The clock is ticking: the case for achieving more rapid control of hypertension, J Clin Hypertens, 12, 323, 10.1111/j.1751-7176.2010.00274.x
Julius, 2004, Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial, Lancet, 363, 2022, 10.1016/S0140-6736(04)16451-9
Bokhour, 2006, How do providers assess antihypertensive medication adherence in medical encounters?, J Gen Intern Med, 21, 577, 10.1111/j.1525-1497.2006.00397.x
Okonofua, 2006, Therapeutic inertia is an impediment to achieving the healthy people 2010 blood pressure control goals, Hypertension, 47, 345, 10.1161/01.HYP.0000200702.76436.4b
Allen, 2009, Nonadherence, clinical inertia, or therapeutic inertia?, J Managed Care Pharm, 15, 690, 10.18553/jmcp.2009.15.8.690
Monane, 1997, The effects of initial drug choice and comorbidity on antihypertensive therapy compliance. Results from a population-based study in the elderly, Am J Hypertens, 10, 697, 10.1016/S0895-7061(97)00056-3
Schroder, 2004, Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD004804
Yarnall, 2003, Primary care: is there enough time for prevention?, Am J Public Health, 93, 635, 10.2105/AJPH.93.4.635
Sarafidis, 2008, Resistant hypertension. An overview of evaluation and treatment, J Am Coll Cardiol, 52, 1749, 10.1016/j.jacc.2008.08.036
Calhoun, 2008, Resistant hypertension: diagnosis, evaluation, and treatment, Hypertension, 51, 1403, 10.1161/HYPERTENSIONAHA.108.189141
2002, Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), JAMA, 288, 2981, 10.1001/jama.288.23.2981
Jamerson, 2008, Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients, N Engl J Med, 359, 2417, 10.1056/NEJMoa0806182
Weder, 2005, The Avoiding Cardiovascular events through COMbination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a comparison of first-line combination therapies, Exp Opin Pharmacother, 6, 275, 10.1517/14656566.6.2.275
Weber, 2010, Cardiovascular events in patient with diabetes and hypertension receiving renin-angiotensin system blockade plus a diuretic or a calcium channel blocker, J Am Coll Cardiol, 56, 77, 10.1016/j.jacc.2010.02.046
Bakris, 2010, Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomized controlled trial, Lancet, 375, 1173, 10.1016/S0140-6736(09)62100-0
Bakris, 2008, Effects of different ACEI inhibitor combinations on albuminuria: results of the GUARD study, Kidney Intl, 73, 1303, 10.1038/ki.2008.102
Jamerson, 2010, 24-hour ambulatory blood pressure in the ACCOMPLISH trial, N Engl J Med, 363, 98, 10.1056/NEJMc1001410
Kaplan, 2009, The choice of thiazide diuretics. Why chlorthalidone may replace hydrochlorothiazide, Hypertension, 54, 951, 10.1161/HYPERTENSIONAHA.109.135061
Kurtz, 2010, Chlorthalidone: don’t call it “thiazide-like” anymore, Hypertension, 56, 335, 10.1161/HYPERTENSIONAHA.110.156166
Ernst, 2010, Meta-analysis of dose-response characteristics of hydrochlorothiazide and chlorthalidone: effects on systolic blood pressure and potassium, Am J Hypertens, 23, 440, 10.1038/ajh.2010.1
Mason, 2002, Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence, Atherosclerosis, 165, 191, 10.1016/S0021-9150(01)00729-8
Boger-Megiffo, 2010, Myocardial infarction and stroke associated with diuretic based two drug antihypertensive regimens: population based case-control study, BMJ, 340, c103, 10.1136/bmj.c103
Magid, 2010, Comparative effectiveness of angiotensin-converting enzyme inhibitors versus beta-blockers as second-line therapy for hypertension, Circ Cardiovasc Qual Outcomes, 3, 453, 10.1161/CIRCOUTCOMES.110.940874
Bakris, 2010, Effect of combining extended-release carvedilol and lisinopril in hypertension: results of the COSMOS study, J Clin Hypertens, 12, 678, 10.1111/j.1751-7176.2010.00341.x
2008, Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial, Lancet, 372, 1174, 10.1016/S0140-6736(08)61242-8
Volpe, 2009, Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials, J Hypetens, 27, 941, 10.1097/HJH.0b013e32832961ed
Egan, 2009, Plasma renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial, Am J Hypertens, 22, 792, 10.1038/ajh.2009.63
Julius, 2006, The Valsartan antihypertensive Long-Term Use Evaluation (VALUE) trial. Outcomes in patients receiving monotherapy, Hypertension, 48, 385, 10.1161/01.HYP.0000236119.96301.f2
Bakris, 2006, Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome, Diabetes Care, 29, 2592, 10.2337/dc06-1373
Kjeldsen, 2006, Effects of valsartan compared to amlodipine in preventing type 2 diabetes in high-risk hypertensive patients: the VALUE study, J Hypertens, 24, 1405, 10.1097/01.hjh.0000234122.55895.5b
Fulop, 2009, C-reactive protein among community-dwelling hypertensives on single-agent antihypertensive treatment, J Am Soc Hypertens, 3, 260, 10.1016/j.jash.2009.03.003
Ridker, 2006, Valsartan, blood pressure reduction, and C-reactive protein. Primary report of the VAL-MARC trial, Hypertension, 48, 1, 10.1161/01.HYP.0000226046.58883.32
Elliott, 2002, Persistence of antihypertensive efficacy after missed doses: comparison of amlodipine and nifedipine gastrointestinal therapeutic system, J Hypertens, 20, 333, 10.1097/00004872-200202000-00025
Li, 2010, Prognostic value of the morning blood pressure surge in 5645 subjects from 8 populations, Hypertension, 55, 1040, 10.1161/HYPERTENSIONAHA.109.137273
Webb, 2010, Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systemic review and meta-analysis, Lancet, 375, 906, 10.1016/S0140-6736(10)60235-8
Matsui, 2009, Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients, Hypertension, 54, 716, 10.1161/HYPERTENSIONAHA.109.131466
Siragy, 2010, Improving vascular function in hypertension: potential benefits of combination therapy with amlodipine and renin-angiotensin-aldosterone system blockers, J Hypertens, 28, 2, 10.1097/HJH.0b013e328332bcf0
Reichek, 2009, Magnetic resonance imaging left ventricular mass reduction with fixed-dose angiotensin-converting enzyme inhibitor-based regimens in patients with high-risk hypertension, Hypertension, 54, 731, 10.1161/HYPERTENSIONAHA.109.130641
Fogari, 2006, Antihypertensive drugs and fibrinolytic function, Am J Hypertens, 19, 1293, 10.1016/j.amjhyper.2006.04.013
Boutouyrie, 2010, Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination. The EXPLOR study, Hypertension, 55, 1314, 10.1161/HYPERTENSIONAHA.109.148999
2010, Effects of intensive blood-pressure control in type 2 diabetes mellitus, N Engl J Med, 362, 1575, 10.1056/NEJMoa1001286